Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNCE, but not buy additional shares or sell existing shares.
View CNCE analyst ratings or view top-rated stocks.

5 brokerages have issued 1 year target prices for Concert Pharmaceuticals' stock. Their CNCE share price forecasts range from $17.00 to $25.00. On average, they anticipate the company's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price.
View analysts price targets for CNCE or view top-rated stocks among Wall Street analysts.

Concert Pharmaceuticals' stock was trading at $5.84 at the beginning of 2023. Since then, CNCE stock has increased by 42.8% and is now trading at $8.34.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our CNCE earnings forecast.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its earnings results on Monday, November, 7th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.01. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.33 million.

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (2.70%), Assenagon Asset Management S.A. (1.60%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends.

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNCE stock can currently be purchased for approximately $8.34.

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $399.82 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.